News

Euclid Systems Names Key Leadership Hires and Announces Major Facility Expansion

Euclid Systems Corporation, a global leader in advanced orthokeratology and proactive myopia management, today announced two exceptional additions to its leadership team as well as the expansion of its manufacturing facility in Sterling, Virginia. The changes come at a time when Euclid’s next-generation of Ortho-K lens, Euclid MAX, is helping to combat the battle against the myopia epidemic, which is expected to affect approximately 5 billion people worldwide by 2050.1

Space at the Euclid facility in Sterling, Virginia, has now been expanded over 40%. Additions include larger manufacturing space, quality assurance labs, offices, and engineering/R&D space.

“With the launch of our game-changing Euclid Max Ortho-K lens this year, we have entered a very exciting time at Euclid. But our steadfast commitment to innovation is not taking a break. We’ve just expanded our manufacturing space and employee resources for the second time in three years and continue to grow our leadership team for future expansion,” said Euclid Systems CEO, Joseph Boorady. “We’re pleased to welcome Greg Endicott and Mark Mercier, who bring decades of experience, innovation, and results in fast-paced healthcare environments. Their knowledge and leadership, as well as the brick-and-mortar expansion of our facilities, help fortify Euclid’s growth as a cutting-edge world leader in myopia management technologies.”

As Chief Information Officer (CIO), Greg Endicott will lead Euclid’s strategic technology program and drive business initiatives in collaboration with global business leaders, including exploration of emerging technologies and new strategies. Previously, Mr. Endicott had a leadership role at Baxter Bioscience and was inaugural CIO of two scientific research companies. New Senior Director of Operations is Mark Mercier, a transformation specialist with decades of experience in contact lens manufacturing at Bausch+Lomb. Mr. Mercier will drive efficient methodologies throughout Euclid’s manufacturing and fulfillment.

Additional information on Euclid’s state-of-the-art manufacturing facility, and what differentiates Euclid in the industry, may be viewed in the video presentation, “Euclid – Your Partner in Myopia Management”.

To learn more visit the link.

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin